View details of this raise on Seedstage

Bellevue, WA

Developing a novel intravesical drug delivery platform for bladder health.

• Innovative Drug Delivery: Watershed Therapeutics has developed a buoyant, shape-changing polymer rod for extended bladder drug residence time.
• Lead Programs: The platform targets Non-Muscle Invasive Bladder Cancer and recurrent urinary tract infections.
• Capital Efficiency: The company operates with exceptional capital efficiency, having raised $8.3M and achieved multiple first-in-human studies.
• Experienced Leadership: Guided by a network of urologists and advisors, ensuring alignment with patient and physician needs.
• Regulatory Strategy: Regulatory alignment with FDA on 505(b)(2) pathway, allowing direct entry into Phase 2 patient trials.

Watershed Therapeutics is developing a novel intravesical drug delivery platform aimed at extending bladder drug residence time. The company has created a buoyant, shape-changing polymer rod combined with a sustained-release drug matrix to address the challenge of the bladder’s natural tendency to expel drugs quickly. This technology is designed to provide a comfortable, long-term solution for bladder cancer and recurrent urinary tract infections (rUTI). The platform supports multiple agents and indications, with lead programs targeting Non-Muscle Invasive Bladder Cancer (NMIBC) and rUTI.

The current fundraising aims to support the completion of an OUS Phase 1b trial in NMIBC, maintain lean operations, and prepare for IND filings. Watershed Therapeutics operates with capital efficiency, having raised $8.3M since inception and achieving multiple first-in-human studies. The company is guided by a network of experienced urologists and advisors, ensuring alignment with patient and physician needs. The funds will be used for product development, clinical trials, and regulatory preparations, positioning the company for broad adoption and long-term impact in the bladder health market.

Company Info

Watershed Therapeutics develops a novel intravesical drug delivery platform to extend bladder drug residence time for conditions like NMIBC and rUTI.

Watershed Therapeutics is a clinical-stage company focused on developing a novel intravesical drug delivery platform aimed at extending bladder drug residence time. The company’s technology utilizes a shape-changing, buoyant polymer rod combined with a sustained-release drug matrix to address the challenge of the bladder’s natural tendency to expel drugs quickly. This platform supports multiple agents and indications, with lead programs targeting Non-Muscle Invasive Bladder Cancer (NMIBC) and Recurrent Urinary Tract Infections (rUTI).

The company’s lead product is a timed-release intravesical implant designed for comfort and long-term retention, placed via routine office transurethral catheterization. Watershed Therapeutics has demonstrated early safety and comfort in first-in-human studies and is aligned with FDA regulatory pathways to advance into Phase 2 trials. The company operates with a focus on capital efficiency, leveraging a network of expert advisors to guide its clinical and regulatory strategies.